Results 21 to 30 of about 2,489 (185)

Hemolytic Disease of the Fetus and Newborn: Fetal RHD Genotyping, Targeted Prophylaxis, and Prenatal Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemolytic disease of the fetus and newborn (HDFN) remains a significant concern in prenatal care primarily caused by maternal alloimmunization against fetal red blood cell antigens, most commonly the D antigen. Noninvasive fetal RHD genotyping, used as a screening tool, enables targeted antenatal prophylaxis and has been implemented in several
Emilie Thorup, Steffen Thorsen, Morten Hanefeld Dziegiel, Olav Bjørn Petersen, Frederik Banch Clausen   +4 more
wiley   +1 more source

Rare “P-null” Phenotype – Two Case Reports from Western India

Global Journal of Transfusion Medicine
The null phenotype in the P1PK blood group, known as “p,” is extremely rare in the world. Such individuals lack the three high-incidence antigens P, P1, and Pk.
Drashti Gajera, Ujjwal Ahuja, Kamini Gupta, Nidhi Bhatnagar, Swati S. Kulkarni, Pooja D. Kshirsagar   +5 more
doaj   +1 more source

Repeated injection of pooled frozen allogeneic umbilical cord blood mesenchymal stromal cells in 5 flat‐racing horses

Equine Veterinary Education, EarlyView.
Summary Background Tendinopathies in racehorses are challenging to treat, and restoring normal tendon composition remains elusive despite extensive research. Equine multipotent mesenchymal stromal cells (MSC) have shown promise for tendon repair, and various sources of MSC have been described.
A. Merchan Muñoz, N. Coté, T. Koch, S. Mehrpouyan, A. H. Alizadeh, K. A. Russell, G. Monteith, J. Koenig   +7 more
wiley   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source

Molecular Testing in Sickle Cell Disease: From Newborn Screening to Transfusion Care

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Sickle cell disease (SCD) is one of the most frequent monogenic diseases worldwide and a highly heterogeneous and complex disease. SCD care carries several challenges. This includes early and accurate diagnosis as well as optimal red blood cell transfusion matching in this population carrying a high risk of alloimmunization.
Thomas Pincez, Yves D. Pastore
wiley   +1 more source

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

Transfusion Medicine, EarlyView.
Abstract Background and Objectives Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases.
S. Wolf, B. Singh, A. Zaidi, P. Greaves, F. Oyesanya, S. Bennett, B. Kaya, F. Barroso, P. Telfer   +8 more
wiley   +1 more source

Perinatal clinical management of a rare ABh variant blood group

Transfusion Medicine, EarlyView.
Abstract Background The H antigen, precursor of the A and B blood groups, is a high‐prevalence antigen. Very few H antigen‐negative (H−) blood donors are available in the United Kingdom. Case Presentation We present the case of a second pregnancy in a 28‐year‐old woman with the very rare ABh phenotype, and the presence of anti‐H, anti‐A and anti‐B ...
Aritri Mandal, Laura Eastwood, Shane Grimsley, Louise Tilley, Clare Samuelson   +4 more
wiley   +1 more source

Modulation of tumor growth by crossreacting isoantibodies

Biomedicine & Pharmacotherapy, 2002
Tumor cells transfected with strong antigenic epitopes were able to stimulate humoral response against relevant wild-type tumors. Crossreacting immune sera have been obtained by immunizing C57BL/6 mice with OVA-transfected leukemia EL-4 (subclone E.G7) and OVA-transfected melanoma B16 (subclone MO.5) stimulated with interferon-gamma.
P Nguyen, Van Binh, Y S, Lone, H Thien, Duc   +2 more
openaire   +2 more sources

Characterisation of RHD and RHCE variations in blood donors from Jazan Province, Southwestern Saudi Arabia

Transfusion Medicine, EarlyView.
Abstract Background and Objectives Rh is among the most important and highly polymorphic blood group systems due to the proximity of the RHD and RHCE genes, which encode numerous highly immunogenic antigens. However, in areas of Saudi Arabia with a high prevalence of hemoglobinopathy, the molecular characteristics of RHD and RHCE variations are lacking.
Maymoon M. Madkhali, Mayisah Khormy, Abdullah A. Meshi, Bandar Kameli, Khaled Ghazwani, Ohoud Sufyani, Salha Hakami, Yahya Khawaji, Abdullah A. Mobarki, Khaled Essawi, Waleed Hakami, Yara Alyahyawi, Aymen M. Madkhali, Gasim Dobie, Hassan A. Hamali   +14 more
wiley   +1 more source

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source